More importantly, the detection of AR-V7 in PCa CTCs has been correlated with metastatic castrate resistant prostate cancer (CRPC) and resistance against enzalutamide and abiraterone, and potentially superior clinical outcomes for patients on taxane therapy, though response to cabazitaxel has been shown to be independent of AR-V7 status [16,17,18]. Here, AR is linked to posterior cortical atrophy.